Miransertib,1313881-70-7

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Miransertib

CAS No. : 1313881-70-7

MCE 国际站：Miransertib

产品活性：Miransertib (ARQ-092) 是一种有效的，具有口服活性的，选择性和变构性 Akt 抑制剂，对 Akt1，Akt2，Akt3 的 IC₅₀ 分别为 2.7 nM，14 nM 和 8.1 nM。Miransertib 还是有效的 AKT1-E17K 突变蛋白抑制剂，并可用于 PI3K/AKT 驱动的肿瘤和 Proteus 综合征的研究。Miransertib 有效抑制利什曼原虫 (Leishmania)。

研究领域：PI3K/Akt/mTOR  |  Anti-infection

作用靶点：Akt  |  Parasite

In Vitro: In a large panel of cell lines derived from various tumor types, Miransertib (ARQ-092; Compound 21a) shows potent anti-proliferative activity in cell lines containing PIK3CA/PIK3R1 mutations compared to those with wild-type (wt) PIK3CA/PIK3R1 or PTEN loss. Miransertib shows excellent inhibition of p-Akt (S473) and p-Akt (T308) in both AN3CA and A2780 cells. The inhibition of the downstream protein p-PRAS40 (T246) is observed with Miransertib (IC₅₀=0.31 μM).
Miransertib is markedly effective against intracellular amastigotes of L. donovani or L. amazonensis-infected macrophages. Miransertib also enhances mTOR dependent autophagy in Leishmania-infected macrophages.

In Vivo: Miransertib (ARQ-092; Compound 21a) shows good absolute oral bioavailability in rats (5 mg/kg) and monkeys (10 mg/kg) with F values of 62% and 49%, respectively. The half-life is longer in rats compared to monkeys with t_1/2 values of 17 h in rats versus 7 h in monkeys. The C_max is 198 ng/mL and 258 ng/mL and the AUC_inf was 5496 h ng/mL and 2960 h ng/mL in rats and monkeys, respectively.
Miransertib (ARQ-092; Compound 21a) inhibits tumor growth in a human xenograft mouse model of endometrial adenocarcinoma.

相关产品：Drug Repurposing Compound Library Plus  |  Clinical Compound Library Plus  |  Bioactive Compound Library Plus  |  Anti-Infection Compound Library  |  Kinase Inhibitor Library  |  PI3K/Akt/mTOR Compound Library  |  Stem Cell Signaling Compound Library  |  Anti-Cancer Compound Library  |  Clinical Compound Library  |  Autophagy Compound Library  |  Anti-Aging Compound Library  |  Drug Repurposing Compound Library  |  Differentiation Inducing Compound Library  |  Oxygen Sensing Compound Library  |  Anti-COVID-19 Compound Library  |  Glycolysis Compound Library  |  Cytoskeleton Compound Library  |  Orally Active Compound Library  |  Glutamine Metabolism Compound Library  |  Anti-Breast Cancer Compound Library  |  Anti-Lung Cancer Compound Library  |  Anti-Pancreatic Cancer Compound Library  |  Anti-Blood Cancer Compound Library  |  Antiparasitic Compound library  |  Anti-Cancer Metabolism Compound Library  |  Anti-Obesity Compound Library  |  Angiogenesis-Related Compound Library  |  Glucose Metabolism Compound Library  |  Targeted Diversity Library  |  Anti-Liver Cancer Compound Library   |  Rare Diseases Drug Library  |  Anti-Colorectal Cancer Compound Library   |  Anti-Prostate Cancer Compound Library  |  Anti-Pulmonary Fibrosis Compound Library  |  Cancer Stem Cells Compound Library  |  Heterocyclic Compound Library  |  Pain-Related Compound Library  |  Membrane Protein-targeted Compound Library  |  Highly Selective Inhibitors Library  |  Serine/Threonine Kinase Inhibitor Library  |  Chloroquine  |  Puromycin dihydrochloride  |  Deferoxamine mesylate  |  MK-2206 dihydrochloride  |  Hygromycin B  |  SC79  |  Doxycycline hyclate  |  Yoda 1  |  Afatinib  |  Capivasertib  |  Acetaminophen  |  Anisomycin  |  Metronidazole  |  Ipatasertib  |  Kaempferol  |  Amphotericin B  |  Dihydroartemisinin  |  Hydroxychloroquine sulfate  |  Niclosamide  |  Artesunate  |  Berberine chloride  |  Monensin sodium salt  |  Honokiol  |  Chloramphenicol  |  Acridine Orange hydrochloride  |  Ivermectin  |  Oridonin

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Dye Reagents  |  PROTAC  |  Isotope-Labeled Compounds